Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary center.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
11 2023
Historique:
received: 08 05 2023
revised: 28 08 2023
accepted: 08 09 2023
medline: 23 10 2023
pubmed: 22 9 2023
entrez: 21 9 2023
Statut: ppublish

Résumé

To investigate and describe the patterns of regional metastases and recurrences after surgical treatment of oropharyngeal squamous cell cancer (OPSCC). Retrospective study of patients diagnosed with OPSCC from 2006 to 2021 at a tertiary referral center. Only patients treated with surgery including a neck dissection were included. Patients with unknown human papillomavirus (HPV) status, prior head and neck cancer, distant metastases, or synchronous head and neck cancer were excluded. A total of 928 patients were included. 89% were males, the average age was 58.6 years (range: 25.2-87.5), 874 (94%) were HPV(+), and 513 (55.3%) had a tonsil cancer. Among cN + patients, the most commonly involved levels at presentation were level II (85.2%), level III (33.3%), and level IV (9.4%). In cN0 patients, metastases were only observed in level II (16.2%) and level III (9.2%). Nodal recurrence occurred in 48 (5.2%) patients after a median time of 1.0 years (interquartile range: 0.6-2.0). Nodal recurrence incidence was similar in HPV(+) and HPV(-) patients (5.0% vs. 7.4%, p = 0.44). The most common levels for regional recurrence were ipsilateral level II (45.8%), contralateral level II (43.8%), and ipsilateral level V (25.0%). Multivariable analysis revealed that pN was a significant predictor for regional recurrence (p = 0.02). There is no difference in the distribution of regional metastases and recurrences in HPV(+) and HPV(-) OPSCC patients. Our findings align with the established understanding that regional metastases predominantly manifest in the ipsilateral level II-IV at presentation. Moreover, the data support the clinical recommendation to restrict elective neck dissection in cN0 patients to ipsilateral levels IIa and III, excluding level IIb. Regional recurrence is significantly associated with pN status.

Identifiants

pubmed: 37734203
pii: S1368-8375(23)00265-8
doi: 10.1016/j.oraloncology.2023.106569
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106569

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Chadi N Abdel-Halim (CN)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN, United States.

Thomas J O'Byrne (TJ)

Department of Quantitative Health Sciences, Rochester, MN, United States.

Jeffrey P Graves (JP)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN, United States.

Christeebella O Akpala (CO)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN, United States.

Eric J Moore (EJ)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN, United States.

Daniel L Price (DL)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN, United States.

Kendall T Tasche (KT)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN, United States.

Daniel J Ma (DJ)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.

Michelle A Neben-Wittich (MA)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.

Scott C Lester (SC)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.

Mauricio Gamez (M)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.

Katharine A Price (KA)

Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States.

Harry E Fuentes Bayne (HEF)

Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States.

Jean Claude M Rwigema (JCM)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.

Samir H Patel (SH)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.

Lisa A McGee (LA)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.

Jeffrey R Janus (JR)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Jacksonville, FL, United States.

Thomas H Nagel (TH)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Scottsdale, AZ, United States.

Michael L Hinni (ML)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Scottsdale, AZ, United States.

Panayiotis S Savvides (PS)

Department of Medical Oncology, Mayo Clinic, Phoenix, AZ, United States.

Kathryn M Van Abel (KM)

Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN, United States. Electronic address: vanabel.kathryn@mayo.edu.

David M Routman (DM)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH